Sri Kosaraju Joins Penumbra, Inc., as Chief Financial Officer and Head of Strategy

J.P. Morgan Capital Markets Executive Brings Deep Healthcare Financial Experience to Management Team

ALAMEDA, Calif. – March 3, 2015 – Penumbra, Inc., a global interventional therapies company, today announced that Sri Kosaraju is joining the company as chief financial officer and head of strategy. Kosaraju brings more than 15 years of experience in healthcare finance, including most recently heading Healthcare and co-heading TMT Equity Capital Markets at J.P. Morgan. He is joining Penumbra following a standard “garden leave” imposed by J.P. Morgan.

Kosaraju will work closely with Penumbra’s executive team in developing and carrying forward the company’s strategies for continued innovation and growth. Penumbra develops and markets innovative medical devices to treat challenging medical conditions that have significant unmet clinical needs.

“I am excited by the opportunity to join Penumbra,” Kosaraju said. “The company has an impressive track record of innovation and has a strong vision for continued technological developments that will impact patients who have few alternatives. What is more impressive is the Penumbra culture, which lends itself to this mission.”

“The addition of Sri to the senior leadership team further strengthens our company, and he will help us capitalize on our long-term vision for the future,” said Adam Elsesser, chairman and chief executive officer of Penumbra. “Sri’s experience with a variety of private and public companies as well as his relationships in healthcare, and with the investment community, will be invaluable as we write the next chapter in the Penumbra story.”

About Penumbra

Penumbra, Inc. (www.penumbrainc.com) is a global interventional therapies company that develops and markets medical devices to treat challenging medical conditions suffering from significant unmet clinical need. Penumbra’s interventional therapies are used by specialist physician customers to treat patients in three clinical markets: neurovascular disease, peripheral vascular disease and neurosurgery. Penumbra has over 800 employees and its global headquarters is located in Alameda, California, with sales operations around the world.

CONTACT:

Penumbra Media Relations:

Merryman Communications
Betsy Merryman
310-560-8176
betsy@merrymancommunications.com